Trials / Withdrawn
WithdrawnNCT02880345
RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
RADVAX™: A Pilot Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study of a fixed dose of Pembrolizumab in combination with two different regimens of hypofractionated radiation. It is designed to demonstrate the activity and safety of the combination treatment in advanced urothelial cancer patients with prior exposure to PD-1 inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEMBROLIZUMAB | |
| RADIATION | hypofractionated radiation |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-08-01
- Completion
- 2018-12-01
- First posted
- 2016-08-26
- Last updated
- 2019-04-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02880345. Inclusion in this directory is not an endorsement.